JP2024513961A - カンナビジオールの経皮送達 - Google Patents

カンナビジオールの経皮送達 Download PDF

Info

Publication number
JP2024513961A
JP2024513961A JP2023562593A JP2023562593A JP2024513961A JP 2024513961 A JP2024513961 A JP 2024513961A JP 2023562593 A JP2023562593 A JP 2023562593A JP 2023562593 A JP2023562593 A JP 2023562593A JP 2024513961 A JP2024513961 A JP 2024513961A
Authority
JP
Japan
Prior art keywords
once
days
pain
transdermal
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562593A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513961A5 (https=
Inventor
エム． プラコヤニス、フォティオス
ラザー、タマンナ
モディ、ニサーグ
ボロビンスカヤ、マリーナ
Original Assignee
パイク セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/227,591 external-priority patent/US12121617B2/en
Application filed by パイク セラピューティクス インコーポレイテッド filed Critical パイク セラピューティクス インコーポレイテッド
Publication of JP2024513961A publication Critical patent/JP2024513961A/ja
Publication of JP2024513961A5 publication Critical patent/JP2024513961A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023562593A 2021-04-12 2022-04-07 カンナビジオールの経皮送達 Pending JP2024513961A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17/227,591 US12121617B2 (en) 2019-10-14 2021-04-12 Transdermal delivery of cannabidiol
US17/227,591 2021-04-12
PCT/IB2022/053276 WO2022219468A1 (en) 2021-04-12 2022-04-07 Transdermal delivery of cannabidiol

Publications (2)

Publication Number Publication Date
JP2024513961A true JP2024513961A (ja) 2024-03-27
JP2024513961A5 JP2024513961A5 (https=) 2025-04-14

Family

ID=83640369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562593A Pending JP2024513961A (ja) 2021-04-12 2022-04-07 カンナビジオールの経皮送達

Country Status (7)

Country Link
EP (1) EP4322931A4 (https=)
JP (1) JP2024513961A (https=)
CN (1) CN117460503A (https=)
AU (1) AU2022257344A1 (https=)
CA (1) CA3214228A1 (https=)
MX (1) MX2023011948A (https=)
WO (1) WO2022219468A1 (https=)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
JP2020533405A (ja) * 2017-09-15 2020-11-19 漢義生物科技（北京）有限公司 カンナビジオール及び／又はカンナビジバリンを含有する組成物及びその月経困難症の治療における使用
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
JP2022551696A (ja) * 2019-10-11 2022-12-13 パイク セラピューティクス，インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
KR20220044558A (ko) * 2019-08-05 2022-04-08 씨에스 메디카 에이/에스 칸나비디올을 포함하는 외용 제제, 조성물의 제조 방법 및 이의 용도
CA3178878A1 (en) * 2020-04-20 2021-10-28 Fotios M. Plakogiannis Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
US20220047525A1 (en) * 2020-08-17 2022-02-17 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013503206A (ja) * 2009-08-31 2013-01-31 オールトランツ インコーポレイティド マイクロ針を用いた局所及び経皮投与におけるカンナビジオールプロドラッグの使用
US20190133994A1 (en) * 2014-04-18 2019-05-09 Mm Technology Holdings, Llc Transdermal Cannabinoid Patch
JP2018507262A (ja) * 2015-03-02 2018-03-15 アフギン ファーマ, エルエルシーAfgin Pharma, Llc カンナビノイドを用いた、局所局部的神経作用療法
US20170071870A1 (en) * 2015-09-14 2017-03-16 Life Tech Global, Llc Transdermal Delivery of Cannabidiol with Other Active Moieties Including Cannabinoids
JP2020530857A (ja) * 2017-08-14 2020-10-29 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 経皮カンナビジオールゲルを用いた変形性関節症の治療方法
JP2020533405A (ja) * 2017-09-15 2020-11-19 漢義生物科技（北京）有限公司 カンナビジオール及び／又はカンナビジバリンを含有する組成物及びその月経困難症の治療における使用
JP2022551696A (ja) * 2019-10-11 2022-12-13 パイク セラピューティクス，インコーポレイテッド 発作性障害の治療用のカンナビジオール（ｃｂｄ）を含む経皮医薬組成物
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
JP2024514843A (ja) * 2021-04-08 2024-04-03 パイク セラピューティクス インコーポレイテッド 発作性疾患を治療するための医薬組成物及び方法

Also Published As

Publication number Publication date
AU2022257344A1 (en) 2023-10-26
CN117460503A (zh) 2024-01-26
CA3214228A1 (en) 2022-10-20
EP4322931A4 (en) 2025-03-12
MX2023011948A (es) 2023-10-17
WO2022219468A1 (en) 2022-10-20
EP4322931A1 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
US12097293B2 (en) Transdermal delivery of cannabidiol
US12121617B2 (en) Transdermal delivery of cannabidiol
AU2020361741B2 (en) Transdermal compositions comprising cannabidiol (CBD) for use in the treatment of seizure disorders
CA3178878A1 (en) Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain
CN116075296A (zh) 用于治疗多发性硬化症的透皮药物制剂
US20240261235A1 (en) Pharmaceutical Composition And Method For Treating Seizure Disorders
JP2024514843A (ja) 発作性疾患を治療するための医薬組成物及び方法
JP2024514362A (ja) 慢性疼痛の処置のための経皮医薬製剤
JP2024513961A (ja) カンナビジオールの経皮送達
US12268699B2 (en) Transdermal delivery of tetrahydrocannabinol
WO2026018119A1 (en) Transdermal delivery of tetrahydrocannabinol
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250404

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210